Patents by Inventor Claudia BERLIN
Claudia BERLIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10925949Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: September 30, 2020Date of Patent: February 23, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20210023189Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: September 30, 2020Publication date: January 28, 2021Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Patent number: 10898562Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: September 30, 2020Date of Patent: January 26, 2021Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20210008189Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: September 30, 2020Publication date: January 14, 2021Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Patent number: 10813985Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: April 20, 2020Date of Patent: October 27, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Patent number: 10799571Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: April 30, 2020Date of Patent: October 13, 2020Assignee: Immatics Biotechnologies GmbHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20200268862Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: April 20, 2020Publication date: August 27, 2020Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Publication number: 20200254078Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: April 30, 2020Publication date: August 13, 2020Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Patent number: 10668137Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: December 5, 2019Date of Patent: June 2, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20200093905Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: December 5, 2019Publication date: March 26, 2020Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Patent number: 10525115Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: March 29, 2019Date of Patent: January 7, 2020Assignee: Immatics Biotechnologies GmbHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20190275130Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: March 29, 2019Publication date: September 12, 2019Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
-
Patent number: 10286052Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 11, 2018Date of Patent: May 14, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Johannes Kowalewski, Claudia Berlin
-
Publication number: 20180311330Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: July 11, 2018Publication date: November 1, 2018Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Johannes Kowalewski, Claudia Berlin
-
Patent number: 10064924Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: May 8, 2015Date of Patent: September 4, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
-
Publication number: 20150320848Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: ApplicationFiled: May 8, 2015Publication date: November 12, 2015Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane STICKEL, Daniel KOWALEWSKI, Claudia BERLIN